参考文献/References:
1 Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? [J]. Eur J Cancer, 2011, 47(16): 2431-2445.
2 Moore DD, Luu HH. Osteosarcoma [J]. Cancer Treat Res, 2014,162: 65-92.
3 Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success [J]. J Clin Oncol, 2015, 33(27):3029-3035.
4 Dai X, Ma W, He X, et al. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma [J]. Med Sci Monit, 2011, 17(8): RA177-RA190.
5 Hong CW, Zeng Q. Awaiting a new era of cancer immunotherapy [J]. Cancer Res, 2012, 72(15): 3715-3719.
6 Ghafouri- Fard S, Ghafouri- Fard S. siRNA and cancer immunotherapy [J]. Immunotherapy, 2012, 4(9): 907-917.
7 Beard RE, Zheng Z, Lagisetty KH, et al. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells [J]. Immunother Cancer, 2014, 2(25).
8 Toledo SR, Zago MA, Oliveira ID, et al. Insights on PRAME and osteosarcoma by means of gene expression profiling [J]. J Orthop Sci, 2011, 16(4): 458-466.
9 Liu Y, He Z, Feng D, et al. Cytotoxic T- lymphocyte antigen- 4 polymorphisms and susceptibility to osteosarcoma [J]. DNA Cell Biol, 2011, 30(12):1051-1055.
10 Dong Q, Ma X. B7- H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma [J]. Biomed Res Int, 2015: 156432.
11 Wang L, Zhang Q, Chen W, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis [J]. PLoS One, 2013, 8(8): e70689.
12 Mitchison N. Studies on the immunological response to foreign tumor transplants in the mouse I.The role of lymph node cells in conferring immunity by adoptive transfer [J]. J Exp Med, 1955, 102 (2): 157-177.
13 Seton- Rogers S. Tumour immunology: An exhausting metabolic competition [J]. Nat Rev Cancer, 2015, 15(10): 573.
14 Schmeel FC, Schmeel LC, Gast SM, et al. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies [J]. Int J Mol Sci, 2014, 15(8): 14632- 14648.
15 Wongkajornsilp A, Sangsuriyong S, Hongeng S, et al. Effective osteosarcoma cytolysis using cytokine- induced killer cells preinoculated with tumor RNA-pulsed dendritic cells [J]. J Orthop Res, 2005, 23(6): 1460-1466.
16 Todorovic M, Mesiano G, Gammaitoni L, et al. Ex vivo allogeneic stimulation significantly improves expansion of cytokine- induced killer cells without increasing their alloreactivity across HLA barriers [J]. J Immunother, 2012, 35(7): 579-586.
17 Rosenberg S, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin- 2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [J]. N Engl J Med, 1988, 319(25): 1676-1680.
18 Théoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors:use as a possible therapeutic approach of osteosarcoma [J]. BMC Cancer, 2005, 5: 123.
19 Fritzsching B, Fellenberg J, Moskovszky L, et al. CD8(+)/FOXP3(+)- ratio in osteosarcoma microenvironment separates survivors from non- survivors: a multicenter validated retrospective study [J]. Oncoimmunology, 2015, 4(3): e990800.
20 Karimi S, Chattopadhyay S, Chakraborty NG. Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy [J]. Immunology, 2015, 144(2): 186-196.
21 Wang W, Wang J, Song H, et al. Cytotoxic T-lymphocyte antigen-4 + 49G/A polymorphism is associated with increased risk of osteosarcoma [J]. Genet Test Mol Biomarkers, 2011, 15(7/8): 503-506.
22 Liu S, Geng P, Cai X, et al. Comprehensive evaluation of the cytotoxic T- lymphocyte antigen- 4 gene polymorphisms in risk of bone sarcoma [J]. Genet Test Mol Biomarkers, 2014, 18(8): 574-579.
23 Contardi E, Palmisano GL, Tazzari PL, et al. CTLA- 4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction [J]. Int J Cancer, 2005, 117(4): 538-550.
24 Lussier DM, O’neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD- 1/PD- L1 interactions [J]. J Immunother, 2015, 38(3): 96-106.
25 Lussier DM, Johnson JL, Hingorani P, et al. Combination immunotherapy with α- CTLA- 4 and α- PD- L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma [J]. J Immunother Cancer, 2015, 3: 21.
26 Sun C, Sun HY, Xiao WH, et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell- based immunotherapy [J]. Acta Pharmacol Sin, 2015, 36(10): 1191-1199.
27 Kubista B, Trieb K, Blahovec H, et al. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis [J]. Anticancer Res, 2002, 22(2A): 789-792.
28 Guma SR, Lee DA, Yu L, et al. Natural killer cell therapy and aerosol interleukin- 2 for the treatment of osteosarcoma lung metastasis [J]. Pediatr Blood Cancer, 2014, 61(4): 618-626.
29 Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells [J]. Cancer Res, 2013, 73(6): 1777-1786.
30 Buddingh EP, Schilham MW, Ruslan SE, et al. Chemotherapyresistant osteosarcoma is highly susceptible to IL- 15- activated allogeneic and autologous NK cells [J]. Cancer Immunol Immunother, 2011, 60(4): 575-586.
31 Kubo T, Shimose S, Matsuo T, et al. Interferon- α/β receptor as a prognostic marker in osteosarcoma [J]. J Bone Joint Surg Am, 2011, 93(6): 519-526.
32 Zhao J, Wang M, Li Z, et al. Interferon-α suppresses invasion and enhances cisplatin- mediated apoptosis and autophagy in human osteosarcoma cells [J]. Oncol Lett, 2014, 7(3): 827-833.
33 Li Z, Xu Q, Peng H, et al. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell- mediated killing through the Fas/Fas ligand pathway [J]. Int Immunopharmacol, 2011, 11(4): 496-503.
34 Pahl JH, Kwappenberg KM, Varypataki EM, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyltripeptide in combination with interferon-γ [J]. J Exp Clin Cancer Res, 2014, 33: 27.
35 Hirohashi Y, Torigoe T, Tsukahara T, et al. Immune responses to human cancer stem-like cells/cancer-initiating cells [J]. Cancer Sci, 2015.
36 Kissick HT, Sanda MG. The role of active vaccination in cancer immunotherapy: lessons from clinical trials [J]. Curr Opin Immunol, 2015, 35: 15-22.
37 Marcove RC, Southam CM, Levin A, et al. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five [J]. Surg Forum, 1971, 22: 434-435.
38 Southam CM, Marcove RC, Levin AG, et al. Proceedings: Clinical trial of autogenous tumor vaccine for treatment of osteogenic sarcoma [J]. ProcNatl Cancer Conf. 1972, 7:91-100.
39 Krishnadas DK, Shusterman S, Bai F, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE- A1, MAGE- A3 and NY- ESO- 1 for children with relapsed or therapy- refractory neuroblastoma and sarcoma [J]. Cancer Immunol Immunother, 2015, 64(10): 1251-1260.
40 Domingo-Musibay E, Allen C, Kurokawa C, et al. Measles edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma [J]. Cancer Gene Ther, 2014, 21(11): 483-490.
41 王臻, 彭磊, 肖毅, 等. 骨肉瘤细胞与活化 B淋巴细胞融合疫苗的制备及其诱导的抗瘤活性 [J]. 中华骨科杂志, 2001, 21(10): 622-625.
42 郝新保, 范清宇, 张殿忠, 等. 巨噬细胞融合瘤苗对大鼠骨肉瘤的主动性免疫治疗[J]. 第四军医大学学报. 1999, 20(12):1042-1044.
43 Tanaka T, Yui Y, Naka N, et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for antimetastasis therapy [J]. Clin Exp Metastasis, 2013, 30(4): 369-379.
44 Broadhead ML, Dass CR, Choong PF. Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model [J]. Br J Cancer, 2011, 105(10): 1503-1511.
45 Seto M, Yamazaki T, Sonoda J, et al. Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy [J]. Oncol Rep, 2002, 9(2): 337-340.
46 Pellinen R, Hakkarainen T, Wahlfors T, et al. Cancer cells as targets for lentivirus- mediated gene transfer and gene therapy [J]. Int J Oncol, 2004, 25(6): 1753-1762.
47 Zhang Y, Yang CQ, Gao Y, et al. Knockdown of CXCR7 inhibits proliferation and invasion of osteosarcoma cells through inhibition of the PI3K/Akt and β- arrestin pathways [J]. Oncol Rep, 2014, 32 (3): 965-972.
48 Zhao Q, Wang C, Zhu J, et al. RNAi- mediated knockdown of cyclooxygenase2 inhibits the growth,invasion and migration of SaOS2 human osteosarcoma cells:a case control study [J]. J Exp Clin Cancer Res, 2011, 30: 26.